Bayer Submits ‘Son of Nexavar’ Cancer Drug for FDA Approval

Bayer HealthCare Pharmaceuticals’ experimental cancer drug regorafenib — viewed as the “son of Nexavar” from Bayer and Onyx Pharmaceuticals — was submitted Aug. 30 for approval to the Food and Drug Administration, the companies said.
San Francisco Business Times